Aromatase Inhibitor Host Factors Study
Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole
The purpose of this study is to examine how key patient factors, including body size affect how well letrozole suppresses circulating estrogen levels.
This study has two components: (1) Part A - an observational phase to evaluate the impact of vitamin D and obesity on estrogen suppression in post-menopausal women already receiving letrozole treatment, and (2) Part B - an interventional phase for women with body mass index (BMI) > 25 kg/m2 to assess the effect of double AI dose on estrogen levels.
If BMI or other patient factors reduce the effectiveness of letrozole, modifications to treatment recommendations and studies to test higher dosing of letrozole may be needed to maximize the benefit of this treatment and minimize the risk of the breast cancer coming back.
調査の概要
詳細な説明
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X5
- Mount Sinai Hospital
-
Toronto、Ontario、カナダ、M5G 1M9
- Princess Margaret Hospital
-
Toronto、Ontario、カナダ、M5S 1B1
- Women's College Hospital
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Postmenopausal female patients
- histological confirmed diagnosis of estrogen receptor and/or progesterone receptor positive breast cancer (Stage I-III) who have completed local therapy
- Currently prescribed and taking letrozole 2.5 mg daily for a minimum of 3 months
- Willing to provide written informed consent to participate
- for the experimental arm: all of the above and body mass index (BMI) > 25 kg/m2
Exclusion Criteria:
Known abnormal liver or renal function defined by:
- Serum Creatinine > 1.25 times institutional upper limit of normal (ULN) or Calculated Creatinine Clearance < 40 mL/min
- Serum Bilirubin, Aspartate transaminase (AST) or alanine transaminase (ALT) > 1.5 times ULN
- Presence of persistent local or known metastatic cancer
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
他の:Post-menopausal Women Using Adjuvant Letrozole
Part A Routine Care Letrozole; Part B Double Dose Letrozole in overweight/obese participants
|
Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Part A Correlation of Day 29 Estradiol With BMI
時間枠:Day 29
|
Determine if estradiol levels vary with BMI levels after 28 days of monitored adherence to standard dose letrozole, by calculating the Pearson correlation between estradiol and log-transformed BMI
|
Day 29
|
Part A Correlation of Day 29 Estrone With BMI
時間枠:Day 29
|
Determine if estrone levels vary with BMI levels after 28 days of monitored adherence to standard dose letrozole, by calculating the Pearson correlation between estrone and log-transformed BMI
|
Day 29
|
Part A Correlation of Day 29 Estradiol With Vitamin D
時間枠:Day 29
|
Determine if estradiol levels vary with Vitamin D levels levels after 28 days of monitored adherence to standard dose letrozole, by calculating the Pearson correlation between estradiol and log-transformed Vitamin D level
|
Day 29
|
Part A Correlation of Day 29 Estrone With Vitamin D
時間枠:Day 29
|
Determine if estrone levels vary with Vitamin D levels levels after 28 days of monitored adherence to standard dose letrozole, by calculating the Pearson correlation between estrone and log-transformed Vitamin D level
|
Day 29
|
Part B Change in Estradiol Level After Double Dose of Letrozole
時間枠:Day 29 to Day 58
|
In overweight/obese patients enrolled in part B, determine if blood levels of estradiol levels changed from before to after the double dose of letrozole
|
Day 29 to Day 58
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Plasma Letrozole
時間枠:Day 29 and day 58
|
Day 29 and day 58
|
|
Endocrine Symptoms During Part A of Study
時間枠:baseline, day 29 (end of part A)
|
Functional Assessment of Cancer Therapy - Endocrine Sub-scale (FACT-ES) consists of 19 questions answered of a Likert scale.
The sub-scale score ranges from 0 to 76 and the higher the score the better the quality of life
|
baseline, day 29 (end of part A)
|
Endocrine Symptoms During Part B of the Study
時間枠:day 29 (end of part A) and day 58 (end of part B)
|
Functional Assessment of Cancer Therapy - Endocrine Sub-scale (FACT-ES) consists of 19 questions answered of a Likert scale.
The sub-scale score ranges from 0 to 76 and the higher the score the better the quality of life
|
day 29 (end of part A) and day 58 (end of part B)
|
その他の成果指標
結果測定 |
時間枠 |
---|---|
Musculoskeletal Symptoms
時間枠:baseline (day 1), day 29 (end of part A) and day 58 (end of part B)
|
baseline (day 1), day 29 (end of part A) and day 58 (end of part B)
|
協力者と研究者
捜査官
- 主任研究者:Srikala Sridhar, M.D.、Princess Margaret Hospital, Canada
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- AI Host Factors
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data supporting the related manuscript are kept in institutional file storage on an internal server at Lunenfeld-Tanenbaum Research Institute. There are de-identification concerns in small, regionally restricted, clinical datasets which prevent these data being openly available, but data will be made available at reasonable request from the corresponding author for up to and including 5 years from publication of the related manuscript.
For all data requests please contact:
Dr David Cescon, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada. Dave.Cescon@uhn.ca
IPD 共有時間枠
IPD 共有アクセス基準
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
乳房腫瘍の臨床試験
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital; The First Affiliated... と他の協力者完了